Coya Therapeutics (COYA) Competitors $6.47 -0.09 (-1.37%) Closing price 03/31/2025 04:00 PM EasternExtended Trading$6.45 -0.02 (-0.31%) As of 03/31/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock COYA vs. PHAT, TRML, KROS, AUTL, VERV, ZVRA, CRMD, ORIC, ABVX, and SIGAShould you be buying Coya Therapeutics stock or one of its competitors? The main competitors of Coya Therapeutics include Phathom Pharmaceuticals (PHAT), Tourmaline Bio (TRML), Keros Therapeutics (KROS), Autolus Therapeutics (AUTL), Verve Therapeutics (VERV), Zevra Therapeutics (ZVRA), CorMedix (CRMD), ORIC Pharmaceuticals (ORIC), ABIVAX Société Anonyme (ABVX), and SIGA Technologies (SIGA). These companies are all part of the "pharmaceutical products" industry. Coya Therapeutics vs. Phathom Pharmaceuticals Tourmaline Bio Keros Therapeutics Autolus Therapeutics Verve Therapeutics Zevra Therapeutics CorMedix ORIC Pharmaceuticals ABIVAX Société Anonyme SIGA Technologies Coya Therapeutics (NASDAQ:COYA) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, community ranking, valuation, dividends and risk. Does the media favor COYA or PHAT? In the previous week, Coya Therapeutics had 4 more articles in the media than Phathom Pharmaceuticals. MarketBeat recorded 11 mentions for Coya Therapeutics and 7 mentions for Phathom Pharmaceuticals. Coya Therapeutics' average media sentiment score of 0.90 beat Phathom Pharmaceuticals' score of 0.85 indicating that Coya Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Coya Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Phathom Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is COYA or PHAT more profitable? Coya Therapeutics has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -1,292.14%. Phathom Pharmaceuticals' return on equity of 0.00% beat Coya Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Coya TherapeuticsN/A -31.63% -27.76% Phathom Pharmaceuticals -1,292.14%N/A -79.57% Do institutionals & insiders believe in COYA or PHAT? 39.8% of Coya Therapeutics shares are held by institutional investors. Comparatively, 99.0% of Phathom Pharmaceuticals shares are held by institutional investors. 12.0% of Coya Therapeutics shares are held by insiders. Comparatively, 24.1% of Phathom Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Do analysts recommend COYA or PHAT? Coya Therapeutics currently has a consensus price target of $17.00, indicating a potential upside of 162.75%. Phathom Pharmaceuticals has a consensus price target of $22.17, indicating a potential upside of 253.54%. Given Phathom Pharmaceuticals' higher possible upside, analysts clearly believe Phathom Pharmaceuticals is more favorable than Coya Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coya Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Phathom Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has preferable earnings and valuation, COYA or PHAT? Coya Therapeutics has higher earnings, but lower revenue than Phathom Pharmaceuticals. Coya Therapeutics is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCoya Therapeutics$3.55M30.45-$7.99M-$0.98-6.60Phathom Pharmaceuticals$55.25M7.90-$201.59M-$5.35-1.17 Does the MarketBeat Community believe in COYA or PHAT? Phathom Pharmaceuticals received 71 more outperform votes than Coya Therapeutics when rated by MarketBeat users. However, 95.83% of users gave Coya Therapeutics an outperform vote while only 72.31% of users gave Phathom Pharmaceuticals an outperform vote. CompanyUnderperformOutperformCoya TherapeuticsOutperform Votes2395.83% Underperform Votes14.17%Phathom PharmaceuticalsOutperform Votes9472.31% Underperform Votes3627.69% Which has more volatility and risk, COYA or PHAT? Coya Therapeutics has a beta of 0.31, suggesting that its share price is 69% less volatile than the S&P 500. Comparatively, Phathom Pharmaceuticals has a beta of 0.63, suggesting that its share price is 37% less volatile than the S&P 500. SummaryPhathom Pharmaceuticals beats Coya Therapeutics on 9 of the 17 factors compared between the two stocks. Remove Ads Get Coya Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for COYA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart COYA vs. The Competition Export to ExcelMetricCoya TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$109.72M$6.89B$5.63B$7.79BDividend YieldN/A2.81%5.37%4.04%P/E Ratio-9.957.4223.6118.68Price / Sales30.45207.04373.3989.80Price / CashN/A65.6738.1734.64Price / Book2.626.206.734.12Net Income-$7.99M$142.11M$3.20B$247.10M7 Day Performance-1.22%-7.28%-5.33%-3.82%1 Month Performance-8.62%-10.45%-0.40%-6.61%1 Year Performance-33.98%-12.86%7.89%-1.67% Coya Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)COYACoya Therapeutics2.1862 of 5 stars$6.47-1.4%$17.00+162.8%-34.8%$109.72M$3.55M-9.956PHATPhathom Pharmaceuticals3.2905 of 5 stars$6.27-5.0%$22.17+253.5%-41.0%$436.62M$55.25M-1.10110TRMLTourmaline Bio1.9417 of 5 stars$15.21-8.6%$45.20+197.2%-33.6%$427.66MN/A-5.3944Positive NewsGap DownKROSKeros Therapeutics3.5098 of 5 stars$10.19-5.6%$42.33+315.4%-84.6%$413.33M$3.55M-1.96100News CoverageGap DownHigh Trading VolumeAUTLAutolus Therapeutics3.0281 of 5 stars$1.55-6.6%$9.52+514.2%-75.7%$412.45M$10.12M-1.28330Positive NewsGap DownVERVVerve Therapeutics1.7945 of 5 stars$4.57-12.5%$25.50+458.0%-65.6%$405.80M$32.33M-1.86110Gap DownZVRAZevra Therapeutics2.9815 of 5 stars$7.49-4.6%$22.29+197.5%+29.1%$405.33M$23.61M-3.8020Positive NewsCRMDCorMedix2.6034 of 5 stars$6.16-8.6%$15.14+145.8%+45.3%$401.52M$43.47M-7.6030Earnings ReportGap DownHigh Trading VolumeORICORIC Pharmaceuticals4.0926 of 5 stars$5.58-9.1%$18.86+237.9%-59.4%$396.33MN/A-3.0780News CoverageGap DownHigh Trading VolumeABVXABIVAX Société Anonyme2.1572 of 5 stars$6.25-2.8%$38.00+508.0%-56.3%$396.14MN/A0.0061High Trading VolumeSIGASIGA Technologies2.4481 of 5 stars$5.48-1.3%N/A-36.0%$391.48M$138.72M4.5740Analyst RevisionPositive News Remove Ads Related Companies and Tools Related Companies Phathom Pharmaceuticals Competitors Tourmaline Bio Competitors Keros Therapeutics Competitors Autolus Therapeutics Competitors Verve Therapeutics Competitors Zevra Therapeutics Competitors CorMedix Competitors ORIC Pharmaceuticals Competitors ABIVAX Société Anonyme Competitors SIGA Technologies Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:COYA) was last updated on 4/1/2025 by MarketBeat.com Staff From Our PartnersNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredNew “Trump” currency proposed in DCA former U.S. Presidential Advisor has come forward with a stern warning to investors: “Get out of tech, no...Paradigm Press | SponsoredIs Fort Knox Hiding Less Gold Than We Think? Find Out What That Means for YouWith gold prices recently soaring to record highs over $3,000 an ounce, and central banks rushing to accumulat...The Oxford Club | SponsoredLive Footage From Elon Musk’s “Area 51”What’s happening inside this nondescript building in South Memphis is so incredible… That Elon’s competitor...Brownstone Research | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredTermination: 18F (read immediately)Have you ever heard of the government's 18F program? It helped manage digital services across the governmen...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coya Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Coya Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy COYA Stock Free COYA Stock Alerts